A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone ...
Oct 23, 2023
0
76
A new study from researchers at the University of Colorado Anschutz Medical Campus has identified a less invasive way to treat a subset of head and neck cancers, which could potentially change the standard of care for patients.
Nov 28, 2022
0
45
A combination of two drugs that open the floodgates to an immune system attack on cancer curtailed tumor growth in some patients with non-small cell lung cancer (NSCLC) that was resistant to a single immunotherapy agent, ...
Jan 17, 2022
0
75
Immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab improved progression-free survival (PFS) in patients with newly diagnosed advanced or recurrent endometrial cancer compared with chemotherapy alone, with further ...
Oct 23, 2023
0
0
Immunotherapy can extend the response of some head and neck tumors to treatment, maintaining the anti-tumor effects and preventing them from growing or spreading for longer, a study reports.
Oct 4, 2023
0
1
Adding perioperative durvalumab to neoadjuvant chemotherapy did not adversely impact surgery in patients with resectable NSCLC and was associated with a tolerable surgical safety profile, according to research presented from ...
Sep 11, 2023
0
19
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone ...
Apr 16, 2023
0
4
The Phase II results of the NRG Oncology HN004 trial indicate that radiotherapy (RT) with the PD-L1 inhibitor durvalumab did not improve progression-free survival (PFS) and led to significantly higher rates of locoregional ...
Oct 24, 2022
0
6
Using an existing drug for late-stage kidney cancer at an earlier stage of the disease could reduce the risk of cancer recurring by a third, according to new research.
Jul 11, 2021
0
3
(HealthDay)—Durvalumab results in significantly longer overall survival than placebo among patients with stage III, unresectable non-small cell lung cancer who did not have disease progression after concurrent chemoradiotherapy, ...
Oct 30, 2018
0
0
